Patient Education · Endocrinology
MASLD & Fatty Liver Disease
A guide to metabolic dysfunction–associated steatotic liver disease — why it matters for your metabolic health, and how we detect and treat it.
If you have diabetes, prediabetes, or carry extra weight, your liver health is part of your care here. All assessment and treatment is individualized to your history, risk profile, and goals, and we invite you to contact our office to discuss it.
Understanding the Condition
What is MASLD?
MASLD — metabolic dysfunction–associated steatotic liver disease — is the buildup of excess fat in the liver in someone who also has at least one cardiometabolic risk factor, such as prediabetes or type 2 diabetes, overweight or obesity, high blood pressure, elevated triglycerides, or low HDL cholesterol, and who does not drink alcohol in amounts that would by themselves explain the fat. It is the most common chronic liver condition worldwide, affecting more than a third of adults.
MASLD, MASH, NAFLD — what changed, and why?
In 2023 the major liver societies replaced the older term NAFLD (“nonalcoholic fatty liver disease”) with MASLD, and replaced NASH with MASH (“metabolic dysfunction–associated steatohepatitis”). The new names put the cause — insulin resistance and metabolic dysfunction — front and center, remove the stigma attached to the words “fatty” and “nonalcoholic,” and make the diagnosis a positive one based on identifiable risk factors rather than a diagnosis of exclusion. The conditions describe nearly the same population: in U.S. survey data, about 99% of people who met the old NAFLD definition also meet MASLD criteria.
The spectrum. MASLD covers the whole range — from simple fat (steatosis), through MASH (fat plus inflammation and liver-cell injury), to fibrosis (scarring) and ultimately cirrhosis. Fibrosis stage — how much scarring is present — is the single strongest predictor of long-term outcomes, which is why finding and tracking it early is the goal of everything we do here.
What is “at-risk MASH”?
At-risk MASH means steatohepatitis together with clinically significant fibrosis — stage F2 or higher. This is the group at genuine risk of progressing to cirrhosis, and it is the group screening is designed to find. Among people with type 2 diabetes, roughly 15% to 38% have at-risk MASH.
Why It Matters If You Have Diabetes
How common is MASLD in people with diabetes?
Very common — and routinely missed. About 70% of people with type 2 diabetes in the U.S. have MASLD, roughly 35% have the more progressive MASH, and about 7% already have MASLD-related cirrhosis. Among people with prediabetes, an estimated 37% to 50% have MASLD. People with prediabetes are about 2.5 times more likely to have MASLD, 8.5 times more likely to have significant fibrosis, and nearly 6 times more likely to have advanced fibrosis than those without.
Why should I care about my liver if my diabetes is otherwise managed?
Because the relationship runs both ways and reaches well beyond the liver. MASLD raises the risk of progressing from prediabetes to type 2 diabetes, and it independently raises the risk of cardiovascular disease — the leading cause of death in people with MASLD. It is also associated with chronic kidney disease and several extrahepatic cancers. Approximately one in five people with type 2 diabetes is on a path toward cirrhosis from MASLD if it goes untreated, making it one of the leading reasons for liver transplant in the United States.
Normal liver blood tests do not rule this out. A large share of people with MASLD — even with significant fibrosis — have ALT and AST levels in the “normal” range. Liver enzymes alone are not a reliable screen. This is exactly why we calculate a fibrosis risk score and, when indicated, measure the liver directly rather than relying on enzymes.
How We Diagnose and Stage It
How do you screen for it — what is the two-step pathway?
We follow the screening pathway endorsed by the American Diabetes Association and the American Association of Clinical Endocrinology. The first step is the FIB-4 index, a simple calculation from your age, AST, ALT, and platelet count — inexpensive, and a reliable way to rule advanced fibrosis out. A FIB-4 under 1.3 means low risk and routine re-checking every one to two years. A FIB-4 above 2.67 indicates high risk and prompts referral to a liver specialist. The large middle group — FIB-4 between 1.3 and 2.67 — needs a second-step test that measures the liver directly.
What is the second step, and what do you use here?
The second step is a direct measurement of liver stiffness, which reflects the degree of fibrosis. In our office we use the Siemens ACUSON Sequoia ultrasound system with state-of-the-art ARFI (acoustic radiation force impulse) liver-analysis technology, performing this assessment in a single, painless scan. It combines Auto pSWE (point shear-wave elastography), which quantifies liver stiffness with up to 15 valid measurements in seconds, and UDFF (Ultrasound-Derived Fat Fraction), which quantifies liver fat with clinical utility comparable to MRI-PDFF, classifying steatosis at a fat fraction above 5%. In recent biopsy-controlled studies, point shear-wave elastography performs on par with or better than other ultrasound elastography techniques across every fibrosis stage, with validated thresholds for significant fibrosis, advanced fibrosis, and cirrhosis. Measuring both stiffness and fat in one acquisition lets us stratify your risk precisely and follow it over time — without an MRI or a biopsy.
One scan, two answers. Most fibrosis pathways need separate tests for fat and for stiffness. The Sequoia ARFI platform gives us both — how much fat is in the liver, and how stiff (scarred) it has become — in a single bedside study. That makes our office a complete diagnostic and therapeutic hub for fatty liver disease: we stage it, treat it, and track it over time, all in the setting where your metabolic health is already managed.
How do you read the stiffness numbers?
Liver stiffness is reported in kilopascals (kPa) and interpreted against validated thresholds: below roughly 8 kPa indicates a low likelihood of clinically significant fibrosis; the 8–10 kPa range is intermediate; values above roughly 10 kPa suggest advanced fibrosis, and above 15 kPa raise concern for cirrhosis. MASLD is a disease of the metabolic spectrum, and the great majority of patients are best managed right here, where their diabetes, weight, and cardiovascular risk are already being treated. We reserve referral to a hepatologist for the minority with imaging or clinical signs of advanced fibrosis or cirrhosis. We always read the number alongside your FIB-4 score, your cardiometabolic risk factors, and clinical judgment rather than treating any single value as definitive.
Will I need a liver biopsy?
Usually not. The whole point of the noninvasive pathway — FIB-4 plus elastography — is to spare most people a biopsy. Biopsy is reserved for cases where the noninvasive tests disagree or are inconclusive, or where another liver disease is suspected, and it is performed by the liver specialist, not here.
Are there other causes of a fatty liver you check for first?
Yes. Before attributing fat or elevated liver enzymes to MASLD, we rule out other causes — significant alcohol use, hepatitis B and C, certain medications, and less common conditions — with history and targeted blood work. The CDC recommends at least one-time screening for hepatitis B and C in all adults, and hepatitis C is now curable in nearly everyone.
How We Treat It
What is the foundation of treatment?
Weight loss and lifestyle change. The benefits are dose-dependent: losing about 5% of body weight reduces liver fat, roughly 7–10% is usually needed to reverse steatohepatitis, and 10% or more can drive regression of fibrosis. We pair this with a Mediterranean-style eating pattern — rich in vegetables, whole grains, and healthy fats, low in saturated fat, added sugar, and ultra-processed foods — which has the best long-term cardiometabolic and mortality data, plus at least 150 minutes a week of moderate activity and resistance training two to three times weekly.
Which medications actually help the liver?
For people with type 2 diabetes and MASH, the agents with the best evidence do double duty — treating diabetes or obesity while improving the liver. GLP-1 receptor agonists (semaglutide has the strongest evidence, now supported by a phase 3 trial showing improvement in both steatohepatitis and fibrosis) and pioglitazone both improve steatohepatitis; the dual GIP/GLP-1 agonist tirzepatide is promising in phase 2 data. SGLT2 inhibitors, alongside these agents, also reduce cardiovascular risk. In 2024 the FDA approved resmetirom, a thyroid-hormone-receptor-beta agonist, as the first medication specifically for MASH with F2–F3 fibrosis. We individualize the choice to your diabetes, weight, cardiovascular risk, and liver stage.
This is squarely our wheelhouse. As an endocrinology practice, the same medications we use to manage diabetes and obesity — GLP-1 agonists, pioglitazone, the newer dual agonists — are the ones with proven liver benefit. We can often treat your diabetes, your weight, your cardiovascular risk, and your liver with a single, coordinated plan.
What about medications that do not help the liver?
Metformin, sulfonylureas, DPP-4 inhibitors, and insulin have not been shown to improve steatohepatitis or fibrosis. They remain useful for controlling blood sugar and can be continued for that purpose, but they should not be relied on to treat the liver disease itself. Vitamin E may help selected people without diabetes but is not recommended for those with diabetes or advanced fibrosis on current evidence.
Is surgery ever part of the plan?
For the right candidate, yes. Metabolic (bariatric) surgery produces durable weight loss and improves steatosis in 70–80% of people, with resolution of inflammation in many and fibrosis improvement in 30–40%, plus major cardiovascular benefit. It is considered with caution in compensated cirrhosis and is not recommended in decompensated cirrhosis. We coordinate this through established surgical programs when appropriate.
Alcohol and your liver. If you have MASLD with significant fibrosis (F2 or higher), alcohol should be avoided. In people who already have obesity and diabetes, alcohol works synergistically with metabolic disease to accelerate liver injury, cirrhosis, and liver cancer. We assess alcohol intake as part of routine care, without judgment, because it genuinely changes the trajectory.
Living With and Monitoring MASLD
How often will you re-check my liver?
It depends on your risk tier. If your FIB-4 is low (under 1.3) we generally repeat it every one to two years. If you have significant fibrosis, we follow you more closely — often with annual elastography on the Sequoia and blood-based fibrosis markers — and we watch for any rise, since an increase of about 30% in liver stiffness signals progression. If you are on treatment, we use the same stiffness measurement to confirm you are responding.
Who is on my care team?
MASLD is best managed by a coordinated team. As your endocrinology practice we lead the metabolic side — diabetes, obesity, cardiovascular risk, and the liver-directed medications — and we bring in dietitians, diabetes educators, and, when fibrosis is advanced, gastroenterology or hepatology. The aim is one integrated plan rather than fragmented care.
The bottom line. Cirrhosis from MASLD is largely preventable when caught early. With a simple blood-based score, an in-office ultrasound when needed, lifestyle change, and the right medications, the great majority of people with diabetes or prediabetes can keep fatty liver from ever progressing to serious liver disease — the same way we already protect the eyes, kidneys, and nerves.
A Final Note
If you have diabetes, prediabetes, or obesity, ask us about your liver. A FIB-4 score can be calculated from labs you may already have, and an in-office liver scan takes only minutes. Finding fatty liver early gives us the best possible chance to keep it from ever becoming a problem.